Making the Right Decisions Before It’s Too Late
Selecting GMP hPSC start material is one of the earliest decisions with long-term consequences. Yet most teams approach it with fragmented information, limited time, and an incomplete view of downstream implications.
This Expert Report was created to address that gap.
It consolidates technical, regulatory, IP, and supplier-related considerations into a single, structured, and independent assessment—allowing teams to move forward without months of manual research or reliance on vendor-driven narratives.
Teams typically face one of three challenges - This report addresses all three by bringing fragmented information together into a neutral, comparable framework.
What problem does this actually solve?
-
Evaluating GMP-grade hPSC options requires reviewing scattered publications, supplier materials, and regulatory documentation. This is slow, difficult to standardise, and easy to do incompletely.
-
Early choices may appear viable scientifically but later introduce comparability issues, IP constraints, donor eligibility challenges, or commercial limitations.
-
Information is often obtained directly from suppliers, each optimised to present their own solution rather than the full landscape.
Who should read this report?
Who should read this report?
-
Replace months of independent research with a single, structured analysis
Identify viable GMP-ready options early, before committing significant resources
Reduce the risk of overlooking issues that only emerge later in development
-
Gain a realistic understanding of effort, timelines, and trade-offs
Evaluate existing alternatives before committing to costly in-house development
Avoid common dead ends driven by incomplete early assumptions
-
Support portfolio companies without building in-house evaluation capability
Provide structured, vendor-agnostic insight at early decision points
Enable better guidance without owning downstream technical decisions
-
Support client programs with an independent reference point
Save internal time when assessing potential starting materials
Anchor discussions in neutral analysis rather than vendor claims (Best used as a reference or discussion tool, not redistributed downstream)
Unlock the full potential of your pluripotent cell therapies with our comprehensive Global Analysis of GMP hPSC Start Material.
In-depth analysis of GMP hPSC start materials, ensuring high-quality derivation and manufacturing processes.
Expert consultation providing actionable insights to optimize clinical trial approvals and donor eligibility.
Comprehensive vendor analysis to support strategic decision-making and risk management.
Empower your research and elevate patient outcomes with expert assistance specifically tailored to your pluripotent cell therapy challenges.
Price
“The reports from HOYA strengthened our conviction around our product development strategy and its robustness versus downstream commercial constraints and development realities.
The independent validation provided by the start material analysis and IP landscape work provided a valuable reduction in uncertainty within a relatively short time frame.
These reports, and the expertise at HOYA, are an invaluable source of high quality information. “
Terri Gaskell
CTO, Rinri Therapeutics
The Core Benefit
The value of this report is not access to information. It is time saved, risk reduced, and clarity gained at a moment where early decisions have irreversible consequences.
Exclusive Consultation Included
Each report purchase includes 1.5 hours of one-on-one consulting with the authors. This personalized session allows you to explore the report’s findings, ask specific questions, and receive tailored guidance to implement insights directly into your projects.
Teams usually request this report when
They’re planning GMP manufacturing within 6–18 months
A funding or partnering milestone is approaching
A regulator or CDMO has raised questions about materials
FAQs
-
Each report provides comprehensive insights tailored to support decision-making in PSC-derived cell therapies. The Global GMP Lines Analysis report includes evaluations of key GMP hPSC providers, covering quality standards, regulatory compliance, and manufacturing capabilities. The hiPSC IP Landscape Analysis report offers an in-depth view of the patent landscape, highlighting key competitors, emerging technologies, and IP trends that can guide your strategic planning.
-
Once your purchase is complete, our team will reach out to coordinate a time for the 1.5-hour consultation with the authors. This meeting can be scheduled at a time that suits your needs and will provide an opportunity to dive deeper into the report findings, answer any specific questions, and receive tailored guidance for your projects.
-
After completing your purchase and receiving any necessary vendor approvals, you’ll receive a digital copy of the report directly via email. Our team will also contact you to arrange the included 1.5-hour consultation with the report authors, where we can discuss the findings and answer your questions in depth.
-
Yes, our reports are intended for individual or organizational use by the purchaser only. Unauthorized sharing, distribution, or resale of the report is prohibited. By purchasing, you agree to use the report solely within your organization and not to distribute it externally without prior permission from HOYA Consulting.
Request the GMP Start Material Expert Report
No sales pitch. The report is designed to help you assess readiness and identify gaps—whether you continue with us or not.
HOYA - ABOUT
HOYA - ABOUT
HOYA is your strategic partner in advanced therapy, with deep expertise in pluripotent-derived cell therapies. We help our clients de-risk complex preclinical and commercial challenges, accelerating early research to broad patient access. Leveraging our extensive global network and tailoring solutions to each client’s unique needs, we help drive innovation forward.
Our Services
-
With deep knowledge of hPSC, we offer the hands-on technical expertise needed to advance your research from lab to clinic, ensuring the highest quality and compliance throughout the process.
-
We provide a roadmap for GMP compliance, ensuring your cell therapy products are manufactured with the highest standards of quality.
-
Our strong relationships with leading academic institutions, biotech companies, and industry regulators give you access to a powerful network that can accelerate the development of your therapies.
Advanced Therapy Translation
-
From concept to clinical trials, we guide the entire product development process for hPSC-derived therapies, focusing on the regulatory, technical, and commercial aspects. Our team is well-versed in overcoming the hurdles of product validation and GMP operations.
-
We connect academia with industry leaders to foster collaborations that push the boundaries of cell therapy innovation. By leveraging our extensive network of industrial partners, we help accelerate research into practical, market-ready solutions.
-
Navigating the transition from research to GMP manufacturing can be challenging. We provide pre-GMP support to ensure your processes, materials, and protocols are aligned with regulatory expectations, minimizing delays and ensuring smooth progression to full-scale production.
Research and Development
Finance and Growth
-
Stay ahead of the competition with our in-depth market analysis. We provide actionable insights into emerging trends, competitor activities, and market demands within the cell therapy landscape, empowering you to make informed business decisions.
-
Whether you're at the initial stages of development or looking to commercialize, we offer strategic guidance tailored to your specific needs. Our expertise covers regulatory pathways, product lifecycle management, and commercialization strategies to ensure your cell therapies succeed.
-
We help you identify and secure grant funding to propel your cell therapy projects forward. Our knowledge of funding programs and the right partners will assist in writing and submitting grants in a timely and efficient manner.